Traws Pharma, Inc.

TRAW

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
SEC CIK: 0001130598

SEC filings (opens in a new tab)

No open-market purchases or sales by Traws Pharma, Inc. insiders were filed in the last 90 days; 34 institutions reported holding it in 13F filings for Q2 2026, worth $5.19M in total; no superinvestor holds it.

Q3 2021 vs. Q2 2021

How the institutions holding Traws Pharma, Inc. changed between Q2 2021 and Q3 2021.

All holders in Q3 2021 All holders in Q2 2021

13F holders of TRAW: Q2 2021 compared with Q3 2021
Measure	Q2 2021	Q3 2021	Change
Holders	24	37	+13
Shares	1.57M	2.73M	+1.16M (+73.6%)
Value	$10.9M	$10.5M	−$446.0K (−4.1%)

New holders (17)

Institutions that held Traws Pharma, Inc. at the end of Q3 2021 but not at the end of Q2 2021.

Institutions new to TRAW in Q3 2021
Institution	Shares	Value	% of portfolio
Alyeska Investment Group, L.P.	250,000	$958.0K	0.01%
Gsa Capital Partners LLP	240,658	$922.0K	0.09%
Hudson Bay Capital Management LP	165,684	$635.0K	0.01%
Pura Vida Investments, LLC	150,000	$575.0K	0.04%
CVI Holdings, LLC	128,604	$493.0K	0.03%
Walleye Capital LLC	97,776	$374.0K	0.01%
Citadel Advisors LLC	70,605	$270.0K	0.00%
Susquehanna International Group, LLP	30,354	$116.0K	0.00%
Walleye Trading LLC	27,259	$104.0K	0.00%
Goldman Sachs Group Inc	14,898	$57.0K	0.00%
Engineers Gate Manager LP	10,600	$41.0K	0.00%
Group One Trading, L.P.	6,095	$23.0K	0.00%
FMR LLC	404	$2.00K	0.00%
Royal Bank of Canada	97	$0	0.00%
Cutler Group LP	1	$0	0.00%
Parallel Advisors, LLC	13	$0	0.00%
Gerber Kawasaki Wealth & Investment Management	1	–	–

Sold out (4)

Institutions that held Traws Pharma, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.

Institutions that sold out of TRAW in Q3 2021
Institution	Shares, Q2 2021	Value, Q2 2021
Marshall Wace, LLP	24,345	$169.0K
Jump Financial, LLC	18,500	$128.0K
Deutsche Bank AG	16,359	$113.0K
Two Sigma Advisers, LP	15,633	$108.0K